Pharsight

Omontys patents expiration

Can you believe OMONTYS received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7084245 TAKEDA PHARMS USA Peptides that bind to the erythropoietin receptor
May, 2024

(7 months from now)

US7414105 TAKEDA PHARMS USA Peptides that bind to the erythropoietin receptor
May, 2024

(7 months from now)

US7919118 TAKEDA PHARMS USA Spacer moiety for poly (ethylene glycol) modified peptide based compounds
May, 2024

(7 months from now)

US7528104 TAKEDA PHARMS USA Peptides that bind to the erythropoietin receptor
May, 2024

(7 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7550433 TAKEDA PHARMS USA Erythropoietin receptor peptide formulations and uses
Jun, 2026

(2 years from now)

US7919461 TAKEDA PHARMS USA Erythropoietin receptor peptide formulations and uses
Jun, 2026

(2 years from now)

Omontys is owned by Takeda Pharms Usa.

Omontys contains Peginesatide Acetate.

Omontys has a total of 6 drug patents out of which 0 drug patents have expired.

Omontys was authorised for market use on 27 March, 2012.

Omontys is available in solution;intravenous, subcutaneous dosage forms.

Omontys can be used as treatment of anemia due to chronic kidney disease.

The generics of Omontys are possible to be released after 02 June, 2026.

Drugs and Companies using PEGINESATIDE ACETATE ingredient

Market Authorisation Date: 27 March, 2012

Treatment: Treatment of anemia due to chronic kidney disease

Dosage: SOLUTION;INTRAVENOUS, SUBCUTANEOUS

More Information on Dosage

OMONTYS family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic